SLI
NBIX icon

Sumitomo Life Insurance’s Neurocrine Biosciences NBIX Stock Holding History

Sumitomo Life Insurance’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-9,939
Closed -$710K – 260
2018
Q4 		$710K Buy
9,939
+180
+2% +$17.2K 0.1% 231
2018
Q3 		$1.2M Buy
+9,759
New +$1.11M 0.14% 214

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Life Insurance's NBIX Position: Q1 2019 in Review

Sumitomo Life Insurance sold out of Neurocrine Biosciences (NBIX) in Q1 2019, closing a stake of 9,939 shares — an estimated $710K sold.

Sumitomo Life Insurance first reported a position in NBIX in Q3 2018 and held it in 2 quarters. The position peaked at $1.2M in Q3 2018. 325 funds tracked by Wall St. Rank hold NBIX as of Q1 2019.

  • Sumitomo Life Insurance reported no remaining Neurocrine Biosciences position as of Q1 2019 after selling out during the quarter.
  • Sumitomo Life Insurance sold 9,939 Neurocrine Biosciences shares in Q1 2019, an estimated $710K.
  • Sumitomo Life Insurance first reported a position in Neurocrine Biosciences in Q3 2018 and held it in 2 quarters.
  • Sumitomo Life Insurance's Neurocrine Biosciences position peaked at $1.2M in Q3 2018.
  • 325 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2019.

Based on Sumitomo Life Insurance's 13F filing for Q1 2019, filed 17 Apr 2019.